Angiogenin as a Molecular Target for the Treatment of Prostate Cancer
Authors: Li, Shuping; Ibaragi, Soichiro; Hu, Guo-fu
Source: Current Cancer Therapy Reviews, Volume 7, Number 2, May 2011 , pp. 83-90(8)
Publisher: Bentham Science Publishers
Abstract:Angiogenin (ANG), a 14 kDa angiogenic ribonuclease, is upregulated in human prostate cancers, especially in hormone refractory diseases, and is the highest upregulated gene in Akt-driven prostate intraepithelial neoplasia (PIN) in mice. ANG has been shown to undergo nuclear translocation in both prostate cancer cells and cancer-associated endothelial cells where it binds to the promoter region of ribosomal DNA (rDNA) and stimulates ribosomal RNA (rRNA) transcription. ANG thus plays an essential role in prostate cancer progression by stimulating both cancer cell proliferation and tumor angiogenesis. A variety of ANG antagonists, including its antisense oligonucleotide, siRNA, soluble binding proteins, monoclonal antibody, enzymatic inhibitors, and nuclear translocation blockers, have all been shown to inhibit prostate cancer in various animal models. Accumulating evidence indicates that ANG is a molecular target for prostate cancer drug development.
Keywords: Angiogenin; Neomycin; adenocarcinoma; aminoglycoside; androgen-independence; angiogenesis; chemotherapeutic agents; hyperplasia; immunohistochemical; oligonucleotide; prostate cancer; prostate intraepithelial neoplasia; rRNA transcription; synergistic effect
Document Type: Research Article
Publication date: 2011-05-01
- Current Cancer Therapy Reviews publishes frontier reviews on all the latest advances in clinical oncology, cancer therapy and pharmacology. The journal's aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in cancer therapy.